osteosarcoma epidemiology forecast

Osteosarcoma Insights and Trends

• Osteosarcoma is an uncommon but highly aggressive bone malignancy characterized by rapid local progression, early metastatic potential, and complex molecular alterations that contribute to disease heterogeneity and poor clinical outcomes.
• In 2025, the 7MM accounted for approximately 2,200 osteosarcoma incident cases, which are expected to rise by the year 2036.
• According to DelveInsight’s estimates, there were nearly 100 incident cases of osteosarcoma in males and nearly 80 cases in female in Japan in 2025.
• Despite advances in diagnostic technologies, distinguishing aggressive disease phenotypes at an early stage remains challenging, contributing to persistent uncertainty in clinical decision-making and long-term outcome prediction.
• Limited disease occurence restricts the availability of large-scale clinical and molecular datasets, hindering efforts to fully characterize epidemiological trends and prognostic factors across patient populations.
• Osteosarcoma continues to impose a substantial clinical burden due to its aggressive nature, frequent metastatic spread, and the challenges associated with accurately assessing disease progression and recurrence risk.

DelveInsight’s “Osteosarcoma – Epidemiology Forecast – 2036” report delivers an in depth understanding of osteosarcoma, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, Spain and the United Kingdom
• Asia-Pacific: Japan

Osteosarcoma- Understanding

Osteosarcoma Overview and Diagnosis

Osteosarcoma is the most common primary malignant bone tumor affecting children, adolescents, and young adults. It is a highly aggressive malignancy characterized by rapid progression, strong invasiveness, and a high mortality rate, posing a significant threat to human health. Osteosarcoma originates from mesenchymal tissue composed of spindle-shaped stromal cells capable of producing osteoid or bone-like tissue. The tumor most commonly develops in the metaphysis of long tubular bones, particularly the distal femur, proximal tibia, and proximal humerus, whereas involvement of the spine, pelvis, and sacrum is relatively uncommon. In most cases, patients present with a solitary lesion.

The diagnosis of osteosarcoma requires a multidisciplinary approach due to the complexity of primary bone malignancies. Among the serum biomarkers studied, alkaline phosphatase (ALP) is the most valuable diagnostic marker and is positively associated with tumor volume, providing both diagnostic and prognostic information. Lactate dehydrogenase (LDH) may also correlate with tumor burden, although it is less specific and primarily reflects increased metabolic activity. Diagnostic evaluation typically begins with plain radiographs of the affected bone and nearby joint. If abnormalities are detected, MRI is used to assess local soft-tissue extension, while CT scans help evaluate pulmonary metastases. Bone scintigraphy (BS), often combined with CT, is utilized to detect skeletal metastases. The presence of metastatic disease at diagnosis remains one of the strongest predictors of clinical outcome and survival in osteosarcoma patients.

Further details are provided in the report.

Osteosarcoma Epidemiology

Key Findings from Osteosarcoma Epidemiological Analysis and Forecast

• According to DelveInsight’s analysis, the US had nearly 1,120 incident cases of osteosarcoma in 2025, and it is projected to rise in the coming years.
• In the US, the 0–24 years age group accounted for the largest number of osteosarcoma cases, with nearly 600 cases in 2025, followed by the 25–59 years age group with more than 300 cases and the 60+ years age group with nearly 200 cases.
• According to DelveInsight’s estimates, there were approximately 500 incident cases of osteosarcoma in males and around 400 cases in female in EU4 and the UK in 2025.
• In 2025, the osteoblastic subtype represented the highest number of cases, accounting for more than 110 cases, followed by the chondroblastic subtype with nearly 30 cases. The “others” category accounted for approximately 15 cases, while fibroblastic and parosteal subtypes each contributed more than 10 cases, and the telangiectatic subtype accounted for more than 5 cases in Japan.
• In 2025, Grade IV osteosarcoma represented approximately 56% of grade-specific cases in Japan, followed by Grade III at 28%, while Grade II and Grade I accounted for about 8% and 8%, respectively, highlighting the predominance of high-grade disease at diagnosis.

Industry Experts and Physician Views for Osteosarcoma

To keep up with osteosarcoma dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the bronchiectasis epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the University of California, Harvard Medical School, Vanderbilt-Ingram Cancer Center, KiTZ – Hopp Children's Cancer Center etc. were contacted.

Their opinion helps understand, validate, highlight and provide epidemiological context in osteosarcoma.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of osteosarcoma, explaining their causes, signs and symptoms and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Report Insights

• Osteosarcoma Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year forecast
• Patient Burden Trends (by geography)
• The 7MM Coverage

FAQs

Epidemiology Insights

• What is the forecast period covered in the report?
• How is epidemiological data collected and analyzed for forecasting purposes?
• Out of all EU4 countries and the UK, which country had the highest population of osteosarcoma cases?
• What are the disease risks and burdens of osteosarcoma?
• At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
• What would be the forecasted patient population of osteosarcoma at the 7MM level?

Reasons to Buy

• Insights on osteosarcoma burden and disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the osteosarcoma epidemiology analysis and patient population trends.